These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 28866674)

  • 1. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.
    Collins AJ; Pitt B; Reaven N; Funk S; McGaughey K; Wilson D; Bushinsky DA
    Am J Nephrol; 2017; 46(3):213-221. PubMed ID: 28866674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.
    Nakhoul GN; Huang H; Arrigain S; Jolly SE; Schold JD; Nally JV; Navaneethan SD
    Am J Nephrol; 2015; 41(6):456-63. PubMed ID: 26228532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between serum potassium levels and adverse outcomes in chronic kidney disease: the Fukushima CKD cohort study.
    Tanaka K; Saito H; Iwasaki T; Oda A; Watanabe S; Kanno M; Kimura H; Shimabukuro M; Asahi K; Watanabe T; Kazama JJ
    Clin Exp Nephrol; 2021 Apr; 25(4):410-417. PubMed ID: 33411113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.
    Murat S; Kaya H; Çavuşoğlu Y; Yılmaz MB
    Turk Kardiyol Dern Ars; 2021 Apr; 49(3):198-205. PubMed ID: 33847269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial and Ethnic Differences in Mortality Associated with Serum Potassium in Incident Peritoneal Dialysis Patients.
    Eriguchi R; Obi Y; Soohoo M; Rhee CM; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Nephrol; 2019; 50(5):361-369. PubMed ID: 31522173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study.
    Ahmed MI; Ekundayo OJ; Mujib M; Campbell RC; Sanders PW; Pitt B; Perry GJ; Bakris G; Aban I; Love TE; Aronow WS; Ahmed A
    Int J Cardiol; 2010 Oct; 144(3):383-8. PubMed ID: 19500863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Potassium, Mortality, and Kidney Outcomes in the Atherosclerosis Risk in Communities Study.
    Chen Y; Chang AR; McAdams DeMarco MA; Inker LA; Matsushita K; Ballew SH; Coresh J; Grams ME
    Mayo Clin Proc; 2016 Oct; 91(10):1403-1412. PubMed ID: 27499535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
    JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
    Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyskalemia, its patterns, and prognosis among patients with incident heart failure: A nationwide study of US veterans.
    Matsushita K; Sang Y; Yang C; Ballew SH; Grams ME; Coresh J; Molnar MZ
    PLoS One; 2019; 14(8):e0219899. PubMed ID: 31393910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
    Weir MR; Mayo MR; Garza D; Arthur SA; Berman L; Bushinsky D; Wilson DJ; Epstein M
    J Hypertens; 2017 May; 35 Suppl 1(Suppl 1):S57-S63. PubMed ID: 28129247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up.
    de Rooij ENM; de Fijter JW; Le Cessie S; Hoorn EJ; Jager KJ; Chesnaye NC; Evans M; Windahl K; Caskey FJ; Torino C; Szymczak M; Drechsler C; Wanner C; Dekker FW; Hoogeveen EK;
    Am J Kidney Dis; 2023 Sep; 82(3):257-266.e1. PubMed ID: 37182596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.